Sagimet Biosciences Inc. (0O2)
XSTU 
Summary
0O2 Chart
Sagimet Biosciences Advances Denifanstat: Q3 Earnings And Upcoming Catalysts
Sagimet Biosciences reported a Q3 GAAP EPS loss of -$0.40, missing estimates, but maintains strong momentum with Denifanstat's clinical progress. SGMT's cash position remains robust at $125.5 million, supporting clinical milestones into 2026 despite ongoing R&D-driven losses and disciplined operating spend. Denifanstat advances in Phase 1 combination studies for MASH and acne, with key data readouts expected in 2026 to drive further stock upside.
Sagimet Biosciences Inc. (SGMT) Presents At Cantor Global Healthcare Conference 2025 Transcript
Sagimet Biosciences Inc. (NASDAQ:SGMT ) Cantor Global Healthcare Conference 2025 September 3, 2025 1:35 PM EDT Company Participants David Happel - CEO, President & Director Eduardo Martins - Chief Medical Officer Robert D'Urso - Senior Vice President of New Products Conference Call Participants Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Presentation Prakhar Agrawal Senior Biotech Analyst All right. Hello, everyone.
Sagimet Biosciences Inc. (SGMT) Upgraded to Buy: What Does It Mean for the Stock?
Sagimet Biosciences Inc. (SGMT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sagimet Biosciences Inc. (0O2) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Sagimet Biosciences Inc. ever had a stock split?
Sagimet Biosciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | David A. Happel CEO | XSTU Exchange | US7867001049 ISIN |
| US Country | 14 Employees | - Last Dividend | - Last Split | 14 Jul 2023 IPO Date |
Overview
Sagimet Biosciences Inc., originally founded as 3-V Biosciences, Inc., underwent a rebranding in August 2019 to better reflect its focused mission in the biomedical field. This clinical-stage biopharmaceutical company is at the forefront of developing innovative treatments targeting diseases caused by dysfunctional lipid metabolism pathways. With its incorporation in 2006, Sagimet Biosciences has dedicated its efforts to exploring the potential of fatty acid synthase (FASN) inhibitors. These compounds have shown promise in addressing a variety of conditions linked to lipid metabolism, underlying the company's commitment to advancing healthcare solutions from its headquarters in San Mateo, California. Its research and development pivot around Denifanstat and TVB-3567, reflecting a broader strategy to combat prevalent health issues like nonalcoholic steatohepatitis (NASH) and specific cancer types, along with other conditions such as acne that denote significant unmet medical needs.
Products and Services
-
Denifanstat (Lead Drug Candidate)
As the flagship product of Sagimet Biosciences, Denifanstat signifies a breakthrough in the treatment of nonalcoholic steatohepatitis (NASH), a serious liver condition lacking effective FDA-approved treatments. This innovative therapy, derived from the company’s proprietary research into fatty acid synthase (FASN) inhibitors, showcases Sagimet’s commitment to addressing diseases with significant unmet needs. In addition to NASH, Denifanstat has the potential to offer a novel treatment solution for acne, further demonstrating the broad therapeutic applications of FASN inhibitors in managing conditions linked to lipid metabolism dysfunctions.
-
TVB-3567 (FASN Inhibitor for Cancer)
TVB-3567 stands as Sagimet Biosciences’ pivotal entry into cancer therapy, embodying the company's innovative approach towards leveraging FASN inhibitors against various cancer types. This development aligns with the growing recognition of metabolic pathways, such as those governed by fatty acid synthase, as critical points of intervention in cancer treatment. Sagimet’s pursuit of TVB-3567 underscores a strategic focus on expanding the utility of its FASN inhibitor platform to tackle the complexities of cancer, aiming to provide patients with new, effective therapeutic options.
Contact Information
